<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102436">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01804660</url>
  </required_header>
  <id_info>
    <org_study_id>GN-E-003</org_study_id>
    <nct_id>NCT01804660</nct_id>
  </id_info>
  <brief_title>Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Normal Population</brief_title>
  <acronym>CONTROL</acronym>
  <official_title>A One Year Longitudinal Therapeutically Non-Interventional Study of MSRV-Env Burden in Normal Population as Assessed by PCR and ELISA in Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeNeuro Innovation SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GeNeuro Innovation SAS</source>
  <oversight_info>
    <authority>France Competent Authority: Agence Nationale de Sécurité du Médicament (ANSM)</authority>
    <authority>France Ethics Committee: Comité de Protection des Personnes Sud Est V (CPP)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to explore the levels of MSRV expression by analyzing the levels of MSRV
      transcripts in blood, as well as the levels of the MSRV-Env protein in serum in the normal
      population. This study is important for establishing a baseline to analyze results obtained
      in MS patients (another dedicated study is performed in parallel in MS patients). The study
      will be conducted over one year in a cohort of healthy subjects. The MSRV RNA level,
      MSRV-Env protein levels, reverse transcriptase activity, inflammatory markers assessed by
      cytokines levels will be analysed to define control levels in the normal population and
      their variation during one year. The data obtained in this study in healthy controls will be
      compared to those obtained in a parallel similar study, GN-E-002, conducted in different
      types of MS patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Establish a control value for the levels of MSRV expression in the normal population over time</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Establish a control value for the levels of MSRV expression in the normal population over time using 3 approaches:
MSRV transcripts in PBMC;
MSRV transcripts in plasma;
MSRV-Env protein in serum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers and reverse transcriptase activity in blood.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>25 healthy volunteers</arm_group_label>
    <description>No study treatments administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No study treatments administered</intervention_name>
    <arm_group_label>25 healthy volunteers</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma and PBMC.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Blood donors coming for regular blood draw in the center of transfusion.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signature of an informed consent;

          -  Male or female between 18 and 60 years of age.

        Exclusion Criteria:

          -  Positive serology for hepatitis B or C or HIV;

          -  Acute infection at inclusion;

          -  Severe psychiatric disorder, neurological, inflammatory, or autoimmune disease;

          -  Pregnancy or breastfeeding;

          -  Heavy smokers i.e. more than 10 cigarettes per day;

          -  History of alcohol or drug abuse in the last 3 years;

          -  Participation in a clinical trial (within the last 3 months).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Etablissement Français du Sang Rhône Alpes - 1 route de Taninges</name>
      <address>
        <city>Annemasse</city>
        <zip>74100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 27, 2014</lastchanged_date>
  <firstreceived_date>March 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis (MS)</keyword>
  <keyword>Multiple Sclerosis associated RetroVirus (MSRV)</keyword>
  <keyword>MSRV envelop protein (MSRV-Env)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
